skip to main content
Visitante
Meu Espaço
Minha Conta
Sair
Identificação
This feature requires javascript
Tags
Revistas Eletrônicas (eJournals)
Livros Eletrônicos (eBooks)
Bases de Dados
Bibliotecas USP
Ajuda
Ajuda
Idioma:
Inglês
Espanhol
Português
This feature required javascript
This feature requires javascript
Primo Search
Busca Geral
Busca Geral
Acervo Físico
Acervo Físico
Produção Intelectual da USP
Produção USP
Search For:
Clear Search Box
Search in:
Busca Geral
Or hit Enter to replace search target
Or select another collection:
Search in:
Busca Geral
Busca Avançada
Busca por Índices
This feature requires javascript
This feature requires javascript
Antibody-targeted drugs and drug resistance—Challenges and solutions
Shefet-Carasso, LeeRon ; Benhar, Itai
Drug resistance updates, 2015-01, Vol.18, p.36-46
[Periódico revisado por pares]
Scotland: Elsevier Ltd
Texto completo disponível
Citações
Citado por
Exibir Online
Detalhes
Resenhas & Tags
Mais Opções
Nº de Citações
This feature requires javascript
Enviar para
Adicionar ao Meu Espaço
Remover do Meu Espaço
E-mail (máximo 30 registros por vez)
Imprimir
Link permanente
Referência
EasyBib
EndNote
RefWorks
del.icio.us
Exportar RIS
Exportar BibTeX
This feature requires javascript
Título:
Antibody-targeted drugs and drug resistance—Challenges and solutions
Autor:
Shefet-Carasso, LeeRon
;
Benhar, Itai
Assuntos:
Adcetris
;
Antibodies, Monoclonal - administration & dosage
;
Antibodies, Monoclonal - therapeutic use
;
Antibody–drug conjugates (ADCs)
;
Antibody–drug ratio (ADR)
;
Antigens, Neoplasm - metabolism
;
Antineoplastic Agents - administration & dosage
;
Antineoplastic Agents - therapeutic use
;
Cancer
;
Drug Delivery Systems
;
Drug Design
;
Drug Resistance, Neoplasm
;
Hematology, Oncology and Palliative Medicine
;
Humans
;
Immunoconjugates - administration & dosage
;
Immunoconjugates - therapeutic use
;
Infectious Disease
;
Kadcyla
;
Linker
;
Monoclonal antibodies (mAbs)
;
Multidrug resistance (MDR)
;
Mylotarg
;
Neoplasms - drug therapy
;
Neoplasms - pathology
;
Targeted therapeutics
É parte de:
Drug resistance updates, 2015-01, Vol.18, p.36-46
Notas:
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição:
Abstract Antibody-based therapy of various human malignancies has shown efficacy in the past 30 years and is now one of the most successful and leading strategies for targeted treatment of patients harboring hematological malignancies and solid tumors. Antibody–drug conjugates (ADCs) aim to take advantage of the affinity and specificity of monoclonal antibodies (mAbs) to selectively deliver potent cytotoxic drugs to antigen-expressing tumor cells. Key parameters for ADC include choosing the optimal components of the ADC (the antibody, the linker and the cytotoxic drug) and selecting the suitable cell-surface target antigen. Building on the success of recent FDA approval of brentuximab vedotin (Adcetris® ) and ado-trastuzumab emtansine (Kadcyla® ), ADCs are currently a class of drugs with a robust pipeline with clinical applications that are rapidly expanding. The more ADCs are being evaluated in preclinical models and clinical trials, the clearer are becoming the parameters and the challenges required for their therapeutic success. This rapidly growing knowledge and clinical experience are revealing novel modalities and mechanisms of resistance to ADCs, hence offering plausible solutions to such challenges. Here, we review the key parameters for designing a powerful ADC, focusing on how ADCs are addressing the challenge of multiple drug resistance (MDR) and its rational overcoming.
Editor:
Scotland: Elsevier Ltd
Idioma:
Inglês
Links
View this record in MEDLINE/PubMed
This feature requires javascript
This feature requires javascript
Voltar para lista de resultados
Anterior
Resultado
15
Avançar
This feature requires javascript
This feature requires javascript
Buscando em bases de dados remotas. Favor aguardar.
Buscando por
em
scope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Mostrar o que foi encontrado até o momento
This feature requires javascript
This feature requires javascript